Washington University University of Texas Southwestern VCID Consortium Site

华盛顿大学 德克萨斯大学 西南大学 VCID 联盟网站

• 批准号: 10369469
• 负责人: Hongyu An
• 金额: $ 253.51万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-29 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10369469
• 关键词: African American; Alzheimer' s Disease; Alzheimer' s disease related dementia; Ambulatory Care Facilities; Archives; Area; Biological Markers; Blood; Caregivers; Cerebrovascular Disorders; Cities; Clinical; Clinical Investigator; Clinical Research; Cognitive; Collection; Communities; Data; Dementia; Development; Diffuse; Endothelium; Enrollment; Ensure; Future; Goals; Grant; Growth; Hispanics; Image; Impaired cognition; Informatics; Infrastructure; Institution; Light; Liquid substance; Magnetic Resonance Imaging; Measurement; Measures; Medical center; Network-based; Neurosciences; PGF gene; Participant; Patients; Phenotype; Physiologic pulse; Plasma; Population; Prevention strategy; Procedures; Process; Protocols documentation; Research; Research Infrastructure; Research Personnel; Risk; Risk Factors; Rural; Scanning; Scientist; Signal Transduction; Site; Skeleton; Stroke; Stroke Belt; Texas; Underrepresented Minority; Universities; Validation; Vascular Dementia; Washington; Water; White Matter Hyperintensity; age related; base; biomarker validation; biomedical referral center; cerebrovascular; clinical application; clinical research site; clinical trial implementation; cohort; data sharing; design; ethnic diversity; follow-up; high risk; image archival system; magnetic resonance imaging biomarker; medical schools; metropolitan; neurofilament; neuroimaging; racial and ethnic; racial diversity; recruit; repository; response; serial imaging; sharing platform; socioeconomic diversity; socioeconomics; statistics; stroke risk; success; tertiary care; treatment strategy; vascular cognitive impairment and dementia

PROJECT SUMMARY Vascular contributions to cognitive impairment and dementia (VCID) are the second leading cause of dementia, and a major contributor to Alzheimer’s disease (AD), the most common cause of dementia. Non- invasive biomarkers are critical for the development of prevention and treatment strategies for VCID. The first grant cycle of the MarkVCID consortium identified 11 candidate imaging and fluid biomarkers. In this second grant cycle (RFA-NS-21-005), the VCID consortium will “…carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers….” In response to this RFA, a strong partnership between Washington University School of Medicine and the University of Texas, Southwestern Medical Center (WU-UTSW) has been developed to serve as a new site for the Small Vessel VCID Consortium. Both institutions are high-volume tertiary care referral centers that serve large metropolitan areas with racial, ethnic, socioeconomic, and urban/rural diversity. St. Louis and Dallas are located within or adjacent to the stroke belt—with significant portions of the population at the highest risk of stroke, cerebrovascular disease, and VCID. Because VCID sits at the interface between cerebrovascular risk and age-related dementia, this partnership leverages strengths in both the cerebrovascular and Alzheimer’s disease (AD) research infrastructures that already exist at WU and UTSW. Both Institutions have active AD research centers, and WU is a StrokeNet regional coordinating center, demonstrating a strong track record of collaborative network-based clinical studies. In addition, investigators from both centers are actively leading several independent longitudinal clinical studies that involve participants with VCID or ADRD. We have assembled a group of stroke and AD clinicians, clinical investigators, and scientists who have diverse expertise in VCID and AD pathobiology, clinical trials implementation and management, fluid biomarker collection and measurement, MR image acquisition and processing, informatics and data sharing, and statistics. The collective expertise of the WU-UTSW group will not only permit the implementation of the current VCID biomarker study but will also provide unique proficiencies in refining the design of the current and future biomarker studies for VCID. We will achieve the goals of the VCID consortium through the following aims: Aim 1: Recruit and longitudinally follow a diverse cohort of participants at risk for VCID. Aim 2: Longitudinally acquire and reproducibly measure fluid-based biomarkers for this VCID cohort. Aim 3: Longitudinally acquire and reproducibly process MRI-based biomarkers for the VCID cohort.

项目摘要 对认知障碍和痴呆症（VCID）的血管贡献是痴呆症的第二主要原因，也是阿尔茨海默氏病（AD）的主要贡献者，这是痴呆症的最常见原因。非侵入性生物标志物对于开发VCID的预防和治疗策略至关重要。 Markvcid联盟的第一个赠款周期确定了11种候选成像和流体生物标志物。在第二个赠款周期（RFA-NS-21-005）中，VCID联盟将“…进行全面的多站点临床验证，最多可用于这11个生物标志物中的6个……。”为了回应这一RFA，华盛顿大学医学院与德克萨斯大学西南医学中心（WU-UTSW）之间建立了牢固的伙伴关系，以作为小型VCID联盟的新地点。这两个机构都是高批量的大三级护理转介中心，这些中心为具有种族，种族，社会经济和城市/农村多样性的大型大都市地区提供服务。圣路易斯和达拉斯位于中风带内或附近，大部分人口的中风，脑血管疾病和VCID的风险最高。由于VCID位于脑血管风险与年龄有关的痴呆症之间的界面，因此该伙伴关系在吴和UTSW已经存在的脑血管和阿尔茨海默氏病（AD）研究基础设施中都利用了优势。这两个机构都有活跃的AD研究中心，Wu是一个拼写的区域协调中心，证明了基于网络的临床研究的良好记录。此外，来自两个中心的研究人员正在积极领导几项涉及VCID或ADRD参与者的独立纵向临床研究。我们组建了一组中风和AD临床医生，临床研究人员以及在VCID和AD病理生物学，临床试验实施和管理，流体生物标志物收集和测量，MR图像习得以及处理以及处理以及处理，信息和数据共享以及统计数据方面具有不同专业知识的科学家。 WU-UTSW集团的集体专业知识不仅允许实施当前的VCID生物标志物研究，而且还将提供独特的能力，以完善当前和未来的VCID生物标志物研究的设计。我们将通过以下目标实现VCID财团的目标：AIM 1：招募和纵向遵循有VCID风险的参与者的潜水员队列。目标2：该VCID队列的纵向获取并可重复地测量基于流体的生物标志物。 AIM 3：纵向获取并可重复地处理VCID队列的基于MRI的生物标志物。